The survival of multiple myeloma (MM) patients was significantly improved with the treatment advancement. However, the majority of patients relapsed and progressed eventually with poor prognosis and short survival.¹ New strategies, such as immunotherapy and chimeric antigen receptor (CAR) T cells therapy, appear to be promising treatments for this population.¹ The restricted expression of B-cell maturation antigen (BCMA) on plasma cells has made it an interesting and optimal target for immunotherapy in MM.¹ Two CAR T cells, idecabtagene vicleucel and ciltacabtagene autoleucel, have been previously approved for clinical use in Europe, having impressive results in heavily treated patients.¹ ARI0002h is a CAR T cells made up of a tumor necrosis factor ligand superfamily member 9 (4-1BB) base CAR with a humanized anti-BCMA fragment entirely developed in an academic institution with evidence of in vitro and in vivo efficacy.¹

Despite dramatic improvements in treatment outcomes over the last couple of years, chronic lymphocytic leukemia (CLL) has remained an incurable disease that requires intermittent therapy during episodes of disease progression.¹ In patients with relapsed/refractory (rr) CLL, treatment options often i

Although chronic lymphocytic leukemia (CLL) patients now have a broader selection of treatment options available, therapeutic efficacies of most treatments still largely depend on the patients’ fitness, cytogenetics and previous treatment responses. Some clinically relevant mutations have now been identified to predict

Primary Sjögren’s Syndrome (pSS) is the second most prevalent systemic autoimmune disease characterized by ocular and oral dryness, musculoskeletal pain, profound fatigue, and an increased risk of lymphoma.¹ Although the symptoms are identifiable, pSS remains incurable due to its